Efficacy And SafetyORIC's early data is seen as inline to better than Pfizer in efficacy and safety.
Financial PositionORIC announced a concurrent private placement raising $125MN, supporting its financial position.
Prostate Cancer MarketSolid prostate cancer data with two separate AR inhibitors, along with a clean safety profile, well positions ORIC's drug in the mCRPC market.